Exelixis has launched a Phase 3 trial that will investigate the safety and efficacy of a combination therapy of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) in people with advanced renal cell carcinoma (RCC) whose cancer progressed while being treated with an immune checkpoint inhibitor or shortly thereafter. The pivotal study, called CONTACT-03 (NCT04338269), aims to enroll approximately 500 patients with inoperable, locally advanced, or metastatic RCC. Patient recruitment has started at the City of Hope Comprehensive Cancer Center…
You must be logged in to read/download the full post.
The post Phase 3 Trial Launched to Test Cabometyx-Tecentriq in Advanced Kidney Cancer appeared first on BioNewsFeeds.